FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
Aprea Therapeutics, Inc. APRE — 8-K: Results of Operations and Financial Condition
neutral
The company reported a cash runway into Q1 2028 and is making progress in advancing its oral WEE1 inhibitor APR-1051, with updated interim Phase 1 data to be presented at the EORTC-NCI-AACR Symposium, but there are no significant quantified surprises in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →